PLoS ONE plos plosone PLOS ONE 1932-6203 Public Library of Science San Francisco, CA USA 10.1371/journal.pone.0186537 PONE-D-17-35839 Correction Correction: Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms Ilie Marius Khambata-Ford Shirin Copie-Bergman Christiane Huang Lingkang Juco Jonathan Hofman Veronique Hofman Paul 13 10 2017 2017 12 10 e0186537 2017 Ilie et al This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms

Fig 1 is incorrect. The authors have provided a corrected version here.

10.1371/journal.pone.0186537.g001 Optimised protocols for PD-L1 IHC assays using the 22C3 antibody concentrate on the Dako ASL48 and VENTANA BenchMark ULTRA platforms.

PD-L1, programmed death ligand 1; IHC, immunohistochemistry; ASL48, Autostainer Link 48; DAB, 3,3’-diaminobenzidine tetrahydrochloride.

 Reference Ilie M, Khambata-Ford S, Copie-Bergman C, Huang L, Juco J, Hofman V, et al. (2017) Use of the 22C3 anti–PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. PLoS ONE 12(8): e0183023. https://doi.org/10.1371/journal.pone.0183023 28797130